Medical therapy for pediatric pulmonary arterial hypertension

Journal of Pediatrics

Volumn 157, Issue 4, 2010, Pages 528-532

  Tissot, Cecile ^a,b   Ivy, David Dunbar ^b   Beghetti, Maurice ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; AMINOTRANSFERASE; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; NITRIC OXIDE; OXYHEMOGLOBIN; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTACYCLIN SYNTHASE; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNIPROST; VASCULAR ENDOTHELIAL CADHERIN; ANTIHYPERTENSIVE AGENT; PHOSPHODIESTERASE INHIBITOR;

BLOOD VESSEL CATHETERIZATION; BLOOD VESSEL REACTIVITY; BONE PAIN; CHILDHOOD DISEASE; CHRONIC LUNG DISEASE; CLINICAL TRIAL; CONGENITAL HEART DISEASE; CONNECTIVE TISSUE DISEASE; CONTINUOUS INFUSION; DIARRHEA; DISEASE CLASSIFICATION; DRUG HALF LIFE; DRUG WITHDRAWAL; EISENMENGER COMPLEX; EPISTAXIS; EXERCISE; EXERCISE TOLERANCE; FAMILIAL DISEASE; FLUSHING; HEADACHE; HEART OUTPUT; HEART RIGHT LEFT SHUNT; HEART RIGHT VENTRICLE FAILURE; HEART TRANSPLANTATION; HEMODYNAMICS; HUMAN; HYPOTENSION; IDIOPATHIC DISEASE; JAW PAIN; LIVER TOXICITY; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG VASCULAR RESISTANCE; MALE INFERTILITY; OFF LABEL DRUG USE; PAIN; PATIENT COMPLIANCE; PENIS ERECTION; PORTOPULMONARY HYPERTENSION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SICKLE CELL ANEMIA; SIDE EFFECT; SURVIVAL; SURVIVAL RATE; SYSTEMIC PULMONARY SHUNT; TERATOGENICITY; THROMBOEMBOLISM; VASODILATATION; ALGORITHM; ANEMIA, SICKLE CELL; CHILD; CHRONIC DISEASE; HYPERTENSION, PULMONARY; LUNG DISEASES; SEVERITY OF ILLNESS INDEX;

ALGORITHMS; ANEMIA, SICKLE CELL; ANTIHYPERTENSIVE AGENTS; CHILD; CHRONIC DISEASE; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES; PHOSPHODIESTERASE 5 INHIBITORS; PHOSPHODIESTERASE INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 77956394758     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2010.06.010     Document Type: Article

References (52)

1. V.V. McLaughlin, S.L. Archer, D.B. Badesch, R.J. Barst, H.W. Farber, and J.R. Lindner ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association Circulation 119 2009 2250 2294
2. R.J. Barst, G. Maislin, and A.P. Fishman Vasodilator therapy for primary pulmonary hypertension in children Circulation 99 1999 1197 1208
3. D.D. Ivy, J.A. Feinstein, T. Humpl, and E.B. Rosenzweig Non-congenital heart disease associated pediatric pulmonary arterial hypertension Prog Pediatr Cardiol 27 2009 13 23
4. D.B. Badesch, H.C. Champion, M.A. Sanchez, M.M. Hoeper, J.E. Loyd, and A. Manes Diagnosis and assessment of pulmonary arterial hypertension J Am Coll Cardiol 54 1 Suppl 2009 S55 S66
5. G. Simonneau, I.M. Robbins, M. Beghetti, R.N. Channick, M. Delcroix, and C.P. Denton Updated clinical classification of pulmonary hypertension J Am Coll Cardiol 54 1 Suppl 2009 S43 S54
6. R.L. van Loon, M.T. Roofthooft, M. van Osch-Gevers, T. Delhaas, J.L. Strengers, and N.A. Blom Clinical characterization of pediatric pulmonary hypertension: complex presentation and diagnosis J Pediatr 155 2009 176-82 e1
7. A. Fraisse, X. Jais, J.M. Schleich, S. di Filippo, P. Maragnes, and M. Beghetti Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France Arch Cardiovasc Dis 103 2010 66 74
8. M. Beghetti, M.M. Hoeper, D.G. Kiely, J. Carlsen, B. Schwierin, and E.S. Segal Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program Pediatr Res 64 2008 200 204
9. S.G. Haworth, and A.A. Hislop Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006 Heart 95 2009 312 317
10. E.B. Rosenzweig, J.A. Feinstein, T. Humpl, and D.D. Ivy Pulmonary arterial hypertension in children: diagnostic work up and challenges Prog Pediat Cardiol 27 2009 7 11
11. T. Kulik, M. Mullen, and I. Adatia Pulmonary arterial hypertension associated with congenital heart disease Prog Pediatr Cardiol 27 2009 25 33
12. P.M. Mourani, M. Mullen, and S.H. Abman Pulmonary hypertension in bronchopulmonary dysplasia Prog Pediatr Cardiol 27 2009 43 48
13. S.C. Nelson, B.B. Adade, E.A. McDonough, K.L. Moquist, and J.M. Hennessy High prevalence of pulmonary hypertension in children with sickle cell disease J Pediatr Hematol Oncol 29 2007 334 337
14. M. Berner, M. Beghetti, I. Spahr-Schopfer, I. Oberhansli, and B. Friedli Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart disease Am J Cardiol 77 1996 532 535
15. N. Galie, M.M. Hoeper, M. Humbert, A. Torbicki, J.L. Vachiery, and J.A. Barbera Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur Heart J 30 2009 2493 2537
16. R.J. Barst, J.S. Gibbs, H.A. Ghofrani, M.M. Hoeper, V.V. McLaughlin, and L.J. Rubin Updated evidence-based treatment algorithm in pulmonary arterial hypertension J Am Coll Cardiol 54 1 Suppl 2009 S78 S84
17. J. Sandoval, O. Bauerle, A. Gomez, A. Palomar, M.L. Martinez Guerra, and M.E. Furuya Primary pulmonary hypertension in children: clinical characterization and survival J Am Coll Cardiol 25 1995 466 474
18. M. Beghetti, and N. Galie Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension J Am Coll Cardiol 53 2009 733 740
19. D. Yung, A.C. Widlitz, E.B. Rosenzweig, D. Kerstein, G. Maislin, and R.J. Barst Outcomes in children with idiopathic pulmonary arterial hypertension Circulation 110 2004 660 665
20. D.D. Ivy, M. Calderbank, B.D. Wagner, S. Dolan, A.C. Nyquist, and M. Wade Closed-hub systems with protected connections and the reduction of risk of catheter-related bloodstream infection in pediatric patients receiving intravenous prostanoid therapy for pulmonary hypertension Infect Control Hosp Epidemiol 30 2009 823 829
21. C. Tissot, and M. Beghetti Review of inhaled iloprost for the control of pulmonary artery hypertension in children Vasc Health Risk Manag 5 2009 325 331
22. D.D. Ivy, A.K. Doran, K.J. Smith, G.B. Mallory Jr., M. Beghetti, and R.J. Barst Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension J Am Coll Cardiol 51 2008 161 169
23. P.C. Rimensberger, I. Spahr-Schopfer, M. Berner, E. Jaeggi, A. Kalangos, and B. Friedli Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms Circulation 103 2001 544 548
24. G. Simonneau, R.J. Barst, N. Galie, R. Naeije, S. Rich, and R.C. Bourge Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial Am J Respir Crit Care Med 165 2002 800 804
25. D.D. Ivy, L. Claussen, and A. Doran Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil Am J Cardiol 99 2007 696 698
26. R.N. Channick, H. Olschewski, W. Seeger, T. Staub, R. Voswinckel, and L.J. Rubin Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension J Am Coll Cardiol 48 2006 1433 1437
27. S.H. Abman Role of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension Annu Rev Med 60 2009 13 23
28. L.J. Rubin, D.B. Badesch, R.J. Barst, N. Galie, C.M. Black, and A. Keogh Bosentan therapy for pulmonary arterial hypertension N Engl J Med 346 2002 896 903
29. M. Beghetti Bosentan in pediatric patients with pulmonary arterial hypertension Curr Vasc Pharmacol 7 2009 225 233
30. R.J. Barst, D. Ivy, J. Dingemanse, A. Widlitz, K. Schmitt, and A. Doran Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension Clin Pharmacol Ther 73 2003 372 382
31. E.B. Rosenzweig, D.D. Ivy, A. Widlitz, A. Doran, L.R. Claussen, and D. Yung Effects of long-term bosentan in children with pulmonary arterial hypertension J Am Coll Cardiol 46 2005 697 704
32. R.L. van Loon, E.S. Hoendermis, M.G. Duffels, A. Vonk-Noordegraaf, B.J. Mulder, and H.L. Hillege Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? Am Heart J 154 2007 776 782
33. N. Galie, M. Beghetti, M.A. Gatzoulis, J. Granton, R.M. Berger, and A. Lauer Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study Circulation 114 2006 48 54
34. M. Beghetti, S.G. Haworth, D. Bonnet, R.J. Barst, P. Acar, and A. Fraisse Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study Br J Clin Pharmacol 68 2009 948 955
35. R.J. Barst Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension Expert Opin Pharmacother 8 2007 95 109
36. N. Galie, H. Olschewski, R.J. Oudiz, F. Torres, A. Frost, and H.A. Ghofrani Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2 Circulation 117 2008 3010 3019
37. R.J. Barst, D. Langleben, A. Frost, E.M. Horn, R. Oudiz, and S. Shapiro Sitaxsentan therapy for pulmonary arterial hypertension Am J Respir Crit Care Med 169 2004 441 447
38. A.M. Atz, and D.L. Wessel Sildenafil ameliorates effects of inhaled nitric oxide withdrawal Anesthesiology 91 1999 307 310
39. P. Namachivayam, U. Theilen, W.W. Butt, S.M. Cooper, D.J. Penny, and L.S. Shekerdemian Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children Am J Respir Crit Care Med 174 2006 1042 1047
40. N. Galie, H.A. Ghofrani, A. Torbicki, R.J. Barst, L.J. Rubin, and D. Badesch Sildenafil citrate therapy for pulmonary arterial hypertension N Engl J Med 353 2005 2148 2157
41. T. Humpl, J.T. Reyes, H. Holtby, D. Stephens, and I. Adatia Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study Circulation 111 2005 3274 3280
42. A.A. Karatza, A. Bush, and A.G. Magee Safety and efficacy of sildenafil therapy in children with pulmonary hypertension Int J Cardiol 100 2005 267 273
43. P.M. Mourani, M.K. Sontag, D.D. Ivy, and S.H. Abman Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease J Pediatr 154 2009 379 384
44. J. Nagendran, S.L. Archer, D. Soliman, V. Gurtu, R. Moudgil, and A. Haromy Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility Circulation 116 2007 238 248
45. R.J. Barst, H. Richardson, I. Konourina, and S. Group Oral sildenafil treatment in children with pulmonary arterial hypertension(PAH): results of a double-blind, placebo-controlled, dose-ranging study European Respiratory Journal 34 suppl 53 2009 S3 S4
46. I. Schulze-Neick, P. Hartenstein, J. Li, B. Stiller, N. Nagdyman, and M. Hubler Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease Circulation 108 Suppl. 1 2003 II167 II173
47. C. Stocker, D.J. Penny, C.P. Brizard, A.D. Cochrane, R. Soto, and L.S. Shekerdemian Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery Intensive Care Med 29 2003 1996 2003
48. R.H. Steinhorn, J.P. Kinsella, C. Pierce, G. Butrous, M. Dilleen, and M. Oakes Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension J Pediatr 155 2009 841 847
49. G. Simonneau, L.J. Rubin, N. Galie, R.J. Barst, T.R. Fleming, and A.E. Frost Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial Ann Intern Med 149 2008 521 530
50. D.D. Ivy, A. Doran, L. Claussen, D. Bingaman, and A. Yetman Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan Am J Cardiol 93 2004 943 946
51. A. Micheletti, A.A. Hislop, A. Lammers, P. Bonhoeffer, G. Derrick, and P. Rees Role of atrial septostomy in the treatment of children with pulmonary arterial hypertension Heart 92 2006 969 972
52. B. Hanna, and C. Conrad Lung transplantation for pediatric pulmonary hypertension Progress in Pediatric Cardiology 27 2009 49 55